Levetiracetam May Be Safer for Girls with Epilepsy

Source: Pediatrics international : official journal of the Japan Pediatric Society

Summary

Researchers studied how two common antiepileptic drugs, valproic acid (VPA) and levetiracetam (LEV), affect hormone levels in adolescent girls with epilepsy. The study included 61 girls, with some taking VPA, some taking LEV, and a control group not on these medications. The researchers looked at various hormone levels, menstrual cycles, and physical development to understand the impact of these medications during puberty.

The key findings showed that girls taking VPA had higher levels of thyroid-stimulating hormone (TSH), which could indicate a potential thyroid issue. They also had lower levels of certain adrenal hormones compared to those taking LEV or not on medication. However, there were no significant differences in weight, height, menstrual cycles, or other hormone levels among the groups, suggesting that the overall physical development was similar.

This study is important because it highlights the potential hormonal effects of VPA during a critical time of growth and development in adolescent girls. It suggests that LEV may be a safer option for managing epilepsy in this age group, as it appears to have fewer negative effects on hormone levels. However, the study had limitations, such as a small sample size and a focus on only two medications, which means more research is needed to confirm these findings and explore other treatment options.

Original source